Lupin Evades U.S. Patent Battle With Warner Chilcott For Oral Contraceptives
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - Indian generic drug maker Lupin may have cleared a big hurdle in its pursuit to launch generic versions of Warner Chilcott's oral contraceptive drugs Loestrin 24 Fe and Femcon in the United States as the Irish company - specializing in dermatology and women's health products - decided to back out from a patent lawsuit it filed at the U.S. District Court of Maryland
You may also be interested in...
Lupin Wants To Go Generic With Nexium; AstraZeneca Feels The Heartburn
MUMBAI - Challenging product patents and later reaching a settlement with innovator companies have emerged as a strong business model for Indian generic drug maker Lupin. After settling at least five patent cases over the last two years, Lupin has now taken on AstraZeneca claiming non-infringement of Nexium (esomeprazole) patents in the United States
Lupin Wants To Go Generic With Nexium; AstraZeneca Feels The Heartburn
MUMBAI - Challenging product patents and later reaching a settlement with innovator companies have emerged as a strong business model for Indian generic drug maker Lupin. After settling at least five patent cases over the last two years, Lupin has now taken on AstraZeneca claiming non-infringement of Nexium (esomeprazole) patents in the United States
India's Lupin Strengthens Its Brand Presence With Oscient Pharma's Antara
MUMBAI - For Lupin - the fast emerging Indian generic drug maker - the switch from pure generic drugs in the U.S. to a patented and branded play is happening faster than many analysts expected. Lupin made an audacious $38.61 million bid for bankruptcy-threatened Oscient Pharma's top cardiovascular drug Antara (fenofibrate), and finally clinched the deal while outpacing at least three other generic rivals